Cargando…

Genetic Alterations and Deregulation of Hippo Pathway as a Pathogenetic Mechanism in Bone and Soft Tissue Sarcoma

SIMPLE SUMMARY: Cancer is a genetic disease that is caused by changes in genes controlling cell growth, migration, and differentiation. Usually, cancer cells hijack processes used by healthy cells during organism development. The Hippo pathway is a developmental signaling system with a critical role...

Descripción completa

Detalles Bibliográficos
Autores principales:	Salguero-Aranda, Carmen, Olmedo-Pelayo, Joaquín, de Álava, Enrique, Amaral, Ana Teresa, Díaz-Martín, Juan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9776600/ https://www.ncbi.nlm.nih.gov/pubmed/36551696 http://dx.doi.org/10.3390/cancers14246211

Ejemplares similares

Breakthrough Technologies Reshape the Ewing Sarcoma Molecular Landscape
por: Salguero-Aranda, Carmen, et al.
Publicado: (2020)

Characterization of Human Mesenchymal Stem Cells from Ewing Sarcoma Patients. Pathogenetic Implications
por: Amaral, Ana Teresa, et al.
Publicado: (2014)

Endoglin and MMP14 Contribute to Ewing Sarcoma Spreading by Modulation of Cell–Matrix Interactions
por: Puerto-Camacho, Pilar, et al.
Publicado: (2022)

A Review: Molecular Aberrations within Hippo Signaling in Bone and Soft-Tissue Sarcomas
por: Deel, Michael D., et al.
Publicado: (2015)

Evaluation of NAB2-STAT6 Fusion Variants and Other Molecular Alterations as Prognostic Biomarkers in a Case Series of 83 Solitary Fibrous Tumors
por: Salguero-Aranda, Carmen, et al.
Publicado: (2021)

Pathogenetic and diagnostic significance of microRNA deregulation in peripheral T-cell lymphoma not otherwise specified
por: Laginestra, M A, et al.
Publicado: (2014)

Bone and Soft Tissue Sarcoma
por: Ruggiero, Antonio
Publicado: (2020)

Prevalence of the Hippo Effectors YAP1/TAZ in Tumors of Soft Tissue and Bone
por: Isfort, Ilka, et al.
Publicado: (2019)

Paediatric bone and soft tissue sarcoma
por: Anderson, J
Publicado: (2007)

Immunotherapy for Bone and Soft Tissue Sarcomas
por: Uehara, Takenori, et al.
Publicado: (2015)

Pediatric bone and soft-tissue sarcomas
por: McCarville, Beth
Publicado: (2015)

Cell Cycle Deregulation in Ewing's Sarcoma Pathogenesis
por: Kowalewski, Ashley A., et al.
Publicado: (2011)

DRUGGABLE MM THERAPEUTICS: PATHOGENETIC PATHWAYS
por: Ocio, Enrique M
Publicado: (2022)

p53 expression and its relationship to DNA alterations in bone and soft tissue sarcomas.
por: Wadayama, B., et al.
Publicado: (1993)

Giant melanocytic nevi and soft tissue undergrowth in the left leg: Pathogenetic hypothesis
por: Pavone, Piero, et al.
Publicado: (2019)

A comprehensive evaluation of Hippo pathway silencing in sarcomas
por: Merritt, Nicole M., et al.
Publicado: (2018)

Therapeutic Targets for Bone and Soft-Tissue Sarcomas
por: Miwa, Shinji, et al.
Publicado: (2019)

Updating on Bone and Soft Tissue Sarcomas Staging
por: Guedes, Alex, et al.
Publicado: (2021)

Extremities Soft Tissue Sarcomas, more Common and as Dangerous as Bone Sarcomas
por: Voltan, Karen, et al.
Publicado: (2021)

Clinical practice guidelines for the diagnosis and treatment of patients with soft tissue sarcoma by the Spanish group for research in sarcomas (GEIS)
por: Garcia del Muro, Xavier, et al.
Publicado: (2015)

VE-Cadherin modulates β-catenin/TCF-4 to enhance Vasculogenic Mimicry
por: Delgado-Bellido, Daniel, et al.
Publicado: (2023)

The Pathogenetic Picture
por: Fincke, B.
Publicado: (1891)

Photodynamic Therapy Using Hippo Pathway Inhibitor Verteporfin: A Potential Dual Mechanistic Approach in Treatment of Soft Tissue Sarcomas
por: Rytlewski, Jeffrey D., et al.
Publicado: (2021)

Synovial sarcoma of bone: Sarcoma typically of soft tissues presenting as a primary bone tumor
por: Caracciolo, Jamie T., et al.
Publicado: (2018)

Akt and Hippo Pathways in Ewing's Sarcoma Tumors and Their Prognostic Significance
por: Ahmed, Atif A., et al.
Publicado: (2015)

Descriptive epidemiology of soft tissue and bone sarcomas in Lebanon
por: Bou Zerdan, Maroun, et al.
Publicado: (2022)

Update in Imaging Evaluation of Bone and Soft Tissue Sarcomas
por: Guedes, Alex, et al.
Publicado: (2021)

Correction: Characterization of Human Mesenchymal Stem Cells from Ewing Sarcoma Patients. Pathogenetic Implications
Publicado: (2014)

Epirubicin is not Superior to Doxorubicin in the Treatment of Advanced Soft Tissue Sarcomas.The Experience of the EORTC Soft Tissue and Bone Sarcoma Group
por: Nielsen, Ole S., et al.
Publicado: (2000)

Alteration of Endothelins: A Common Pathogenetic Mechanism in Chronic Diabetic Complications
por: Chakrabarti, Subrata, et al.
Publicado: (2002)

Peripheral Immune Alterations in Major Depression: The Role of Subtypes and Pathogenetic Characteristics
por: Euteneuer, Frank, et al.
Publicado: (2017)

Welcome to PathoGenetics
por: Ballabio, Andrea, et al.
Publicado: (2008)

Notes, Clinical and Pathogenetic
por: Berridge, E. W.
Publicado: (1885)

On the Pathogenetic Effects of Malaria
por: Munson, W. G.
Publicado: (1864)

Clinical and Pathogenetic Notes
por: Berridge, E. W.
Publicado: (1884)

Clinical and Pathogenetic Notes
por: Berridge, E. W.
Publicado: (1891)

Neurodevelopmental alterations and seizures developed by mouse model of infantile hypophosphatasia are associated with purinergic signalling deregulation
por: Sebastián-Serrano, Álvaro, et al.
Publicado: (2016)

IGF1R Signaling in Ewing Sarcoma Is Shaped by Clathrin-/Caveolin-Dependent Endocytosis
por: Martins, Ana Sofia, et al.
Publicado: (2011)

The Role of “Bone Immunological Niche” for a New Pathogenetic Paradigm of Osteoporosis
por: Pagliari, Danilo, et al.
Publicado: (2015)

Hippo Pathway and YAP Signaling Alterations in Squamous Cancer of the Head and Neck
por: Santos-de-Frutos, Karla, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_n9k2kkpeaatsf3atqvt0nst16n